The DCB Academic Research Consortium consensus document provides a classification of DCB technologies and offers clinical suggestions for their use in various coronary lesion and clinical settings.
This consensus document standardizes the classification, lesion preparation, and clinical indications for drug-coated balloons in percutaneous coronary intervention.
The Drug-Coated Balloon (DCB) Academic Research Consortium project originated from the need to overcome the lack of standardization and comparability among studies focusing on drug-coated balloon treatment. The DCB Academic Research Consortium represents a collaborative effort between academic research organizations and the most renowned interventional cardiology societies focusing on percutaneous coronary intervention in Europe, the United States, and Asia. The present consensus document provides a classification of DCB technologies, antiproliferative drugs, and types of elution and coatings. Moreover, by reviewing the available evidence on the use of DCBs for several lesion (restenosis, de novo small and large vessels, bifurcations) and clinical (acute coronary syndromes, diabetes mellitus, multivessel disease, high bleeding risk) settings, it seeks to provide reasonable suggestions for their clinical use. Last, this paper outlines the processes involved in optimal "lesion preparation" before the use of DCBs and the criteria used for assessing results following their use.
“Looking forwards to five years in the future, might it be that we will have arrived at a point where we look back and think how strange it was that the default position for treating de novo coronary lesions requiring revascularisation was the implantation of permanent metallic stents? The current renewed enthusiasm for research and development in drug-coated balloon angioplasty and the prospect of the availability of results from a number of well-designed, large-scale randomised clinical trials comparing the outcomes of patients treated with a drug-coated balloon angioplasty strategy versus a conventional stenting strategy make that prospect rather more likely than at any stage over the last three decades.”
Fezzi et al. (Wed,) conducted a review in Coronary artery disease requiring percutaneous coronary intervention. Drug-Coated Balloons (DCB) was evaluated. The DCB Academic Research Consortium consensus document provides a classification of DCB technologies and offers clinical suggestions for their use in various coronary lesion and clinical settings.